Zynex Faces Class Action Lawsuit Over Fraudulent Overbilling
Analysis based on 22 articles · First reported Feb 23, 2026 · Last updated Mar 01, 2026
The class action lawsuit against Zynex for alleged fraudulent overbilling is likely to negatively impact Zynex's stock price and investor confidence. The involvement of The Travelers Companies and United States===Tricare suggests potential significant financial liabilities and regulatory scrutiny for Zynex, which could lead to further market downturns for the company.
A class action lawsuit has been filed against Zynex and certain of its officers by Bronstein, Gewirtz & Grossman, LLC, on behalf of investors who purchased Zynex securities between February 25, 2021, and December 15, 2025. The lawsuit alleges that Zynex engaged in fraudulent overbilling practices, including shipping products in excess of need and inflating revenue, which drew scrutiny from insurers like United States===Tricare. The Travelers Companies has also commenced a separate action against Zynex and its executives, Thomas Sandgaard, Dan Lucsok, and William Fox, seeking over $23 million in damages for a fraudulent overbilling scheme between 2018 and 2023. The complaint further alleges that Zynex management prioritized aggressive sales strategies over compliance, leading to illegal overbilling and a lack of strong internal controls. These actions are expected to result in adverse consequences for Zynex, including potential removal from insurer networks and penalties from the federal government.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard